248 results
Search Results
2. Update on 1-benzylpiperazine (BZP) party pills
3. Pharmacokinetics of levodopa
4. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations
5. Pharmacokinetic and pharmacodynamic data and models in clinical trials
6. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam
7. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens
8. Medikamentöse Therapie bei Frauen – Was gilt es zu beachten?
9. Strategien zur Vermeidung von Antibiotikaresistenzen
10. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
11. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects
12. Fluoxetine pharmacogenetics in child and adult populations
13. Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects
14. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
15. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
16. Entry-into-humans study with a new direct renin inhibitor
17. Pharmakotherapie im Alter aus internistisch-pneumologischer Sicht
18. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients
19. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
20. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
21. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts
22. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
23. Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes
24. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis
25. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
26. Antimikrobielle Therapie bei Patienten nach Verbrennungstrauma
27. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
28. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation
29. Characterisation of the iterative integral parameter identification method
30. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
31. Macitentan: entry-into-humans study with a new endothelin receptor antagonist
32. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats
33. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics
34. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
35. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
36. The role of population PK–PD modelling in paediatric clinical research
37. Endpoints in pediatric pain studies
38. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
39. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
40. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
41. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
42. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
43. Umfrage zur Arzneimitteldosierung bei Niereninsuffizienz unter nephrologisch tätigen Ärzten
44. Indomethacin Pharmacodynamics Are Altered by Surfactant: A Possible Challenge to Current Indomethacin Dosing Guidelines Created Before Surfactant Availability
45. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
46. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
47. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker
48. Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT®) following oral administration in African malaria patients
49. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
50. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.